News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Deals
ImaRx Therapeutics Acquires Abbokinase
May 8, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TUCSON, Ariz.--(BUSINESS WIRE)--May 8, 2006--ImaRx Therapeutics, Inc., a biopharmaceutical company developing innovative therapies for vascular diseases including stroke, today announced the Company has acquired the thrombolytic drug Abbokinase®.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Arizona
MORE ON THIS TOPIC
Mergers & acquisitions
Kronos Accepts $35M Concentra Buyout as Walls Close In
May 2, 2025
·
2 min read
·
Annalee Armstrong
Earnings
Tariffs Keep Biogen Execs Busy in Q1 but Impacts Expected To Be Minimal
May 1, 2025
·
3 min read
·
Annalee Armstrong
Deals
Novartis Strikes on M&A, Leading a Line of Big Pharmas With Cash to Spend
April 30, 2025
·
5 min read
·
Annalee Armstrong
Mergers & acquisitions
Novartis Drops up to $1.7B to Bolster Oligo Pipeline With Regulus Buy
April 30, 2025
·
2 min read
·
Tristan Manalac